https://www.nytimes.com/2025/05/01/well/metformin-aging-longevity-benefits-risks.html
Prompted by the growing off-label use of geroprotective drugs, a new New York Times feature examines metformin’s candidacy as an “anti-aging” therapy. The piece distills the current evidence base: modest, strain-dependent lifespan extensions in rodents; conflicting observational data in humans; scant randomized trials that show neutral or muscle-blunting effects; and the still-unfunded TAME trial meant to provide hard end-points on cancer, cardiovascular disease, dementia, and mortality.